BridgeBio Pharma Inc
For the period ended Mar 31, 2024. Filed May 2, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 2, 2024
BBIO$78.67+0.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
| Three Months Ended March 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Operating activities: | ||
| Net loss | $(36,160) | $(142,732) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Loss on extinguishment of debt | 26,590 | — |
| Stock-based compensation | 17,057 | 21,907 |
| Accretion of debt | 2,015 | 2,338 |
| Depreciation and amortization | 1,596 | 1,633 |
| Noncash lease expense | 1,069 | 1,032 |
| Accrual of payment-in-kind interest on term loan | — | 3,339 |
| Loss on deconsolidation of PellePharm | — | 1,241 |
| Gain from investment in equity securities, net | (8,136) | (964) |
| Other noncash adjustments | 1,631 | (314) |
| Changes in operating assets and liabilities: | ||
| Receivables from licensing and collaboration agreements | (233,743) | 6,318 |
| Prepaid expenses and other current assets | (3,345) | (3,542) |
| Other assets | 444 | (483) |
| Accounts payable | (5,927) | (3,800) |
| Accrued compensation and benefits | (14,969) | (18,369) |
| Accrued research and development liabilities | 11,168 | (2,556) |
| Operating lease liabilities | (1,595) | (1,250) |
| Deferred revenue | 24,024 | (1,748) |
| Accrued professional and other liabilities | (1,256) | (6,372) |
| Net cash used in operating activities | (219,537) | (144,322) |
| Investing activities: | ||
| Purchases of marketable securities | (44,395) | — |
| Maturities of marketable securities | — | 18,000 |
| Purchases of investments in equity securities | (20,271) | (47,474) |
| Proceeds from sales of investments in equity securities | 63,229 | 42,287 |
| Proceeds from special cash dividends received from investments in equity securities | 25,682 | — |
| Payment for an intangible asset | (797) | — |
| Purchases of property and equipment | (695) | (12) |
| Decrease in cash and cash equivalents resulting from deconsolidation of PellePharm | — | (503) |
| Net cash provided by investing activities | 22,753 | 12,298 |
| Financing activities: | ||
| Proceeds from term loan under Financing Agreement | 450,000 | — |
| Issuance costs and discounts associated with term loan under Financing Agreement | (12,254) | — |
| Repayment of term loan under Loan and Security Agreement | (473,417) | — |
| Proceeds from issuance of common stock through public offerings, net | 315,254 | 143,016 |
| Proceeds from BridgeBio common stock issuances under ESPP | 2,364 | 1,809 |
| Proceeds from stock option exercises, net of repurchases | 537 | 193 |
| Repurchase of RSU shares to satisfy tax withholding | (2,936) | (512) |
| Other financing activities | — | 5,743 |
| Net cash provided by financing activities | 279,548 | 150,249 |
| Net increase in cash, cash equivalents and restricted cash | 82,764 | 18,225 |
| Cash, cash equivalents and restricted cash at beginning of period | 394,732 | 416,884 |
| Cash, cash equivalents and restricted cash at end of period | $477,496 | $435,109 |
Condensed Consolidated Statements of Cash Flows
(Continued)
| Three Months Ended March 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Supplemental Disclosure of Cash Flow Information: | ||
| Cash paid for interest | $35,315 | $22,059 |
| Supplemental Disclosures of Noncash Investing and Financing Information: | ||
| Unpaid issuance costs associated with term loan under Financing Agreement | $3,732 | $— |
| Unpaid public offering issuance costs | $513 | $— |
| Deferred and unpaid issuance costs recorded to "Accrued professional and other accrued liabilities" | $458 | $— |
| Unpaid property and equipment | $70 | $96 |
| Transfers to noncontrolling interests | $(1,857) | $(2,843) |
| Reconciliation of Cash, Cash Equivalents and Restricted Cash: | ||
| Cash and cash equivalents | $475,222 | $407,368 |
| Restricted cash | 131 | 25,503 |
| Restricted cash — Included in “Other assets” | 2,143 | 2,238 |
| Total cash, cash equivalents and restricted cash at end of periods shown in the condensed consolidated statements of cash flows | $477,496 | $435,109 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.